Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,204 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications.
Narins CR, Miller DP, Califf RM, Topol EJ. Narins CR, et al. Among authors: topol ej. J Am Coll Cardiol. 1999 Mar;33(3):647-53. doi: 10.1016/s0735-1097(98)00620-2. J Am Coll Cardiol. 1999. PMID: 10080464 Free article. Clinical Trial.
Prognostic significance of elevated troponin I after percutaneous coronary intervention.
Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM; SYMPHONY and 2nd SYMPHONY Cardiac Markers Substudy Investigators. Cantor WJ, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 5;39(11):1738-44. doi: 10.1016/s0735-1097(02)01877-6. J Am Coll Cardiol. 2002. PMID: 12039485 Free article. Clinical Trial.
Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: an analysis of the PURSUIT Trial. Platelet glycoprotein IIB/IIIA in Unstable angina: Receptor Suppression Using Integrilin Therapy.
Ronner E, Boersma E, Laarman GJ, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: topol ej. J Am Coll Cardiol. 2002 Jun 19;39(12):1924-9. doi: 10.1016/s0735-1097(02)01897-1. J Am Coll Cardiol. 2002. PMID: 12084589 Free article. Clinical Trial.
Abciximab survival advantage following percutaneous coronary intervention is predicted by clinical risk profile.
Kereiakes DJ, Lincoff AM, Anderson KM, Achenbach R, Patel K, Barnathan E, Califf RM, Topol EJ; EPIC Investigators; EPILOG investigators; EPISTENT investigators. Kereiakes DJ, et al. Among authors: topol ej. Am J Cardiol. 2002 Sep 15;90(6):628-30. doi: 10.1016/s0002-9149(02)02568-7. Am J Cardiol. 2002. PMID: 12231090 Clinical Trial. No abstract available.
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial.
Gurm HS, Lincoff AM, Lee D, Tang WH, Jia G, Booth JE, Califf RM, Ohman EM, Van de Werf F, Armstrong PW, Guetta V, Wilcox R, Topol EJ; GUSTO V Trial. Gurm HS, et al. Among authors: topol ej. J Am Coll Cardiol. 2004 Feb 18;43(4):542-8. doi: 10.1016/j.jacc.2003.09.038. J Am Coll Cardiol. 2004. PMID: 14975461 Free article. Clinical Trial.
1,204 results